Anti-CD44 monoclonal antibody A3D8

Drug Profile

Anti-CD44 monoclonal antibody A3D8

Alternative Names: A3D8

Latest Information Update: 26 Apr 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Duke University Medical Center
  • Developer NEXTherapeutics
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action CD44 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; HIV-1 infections; Myeloid leukaemia

Most Recent Events

  • 26 Apr 2007 Discontinued - Preclinical for Acute myeloid leukaemia in USA (unspecified route)
  • 26 Apr 2007 Discontinued - Preclinical for Myeloid leukaemia in France (unspecified route)
  • 26 Apr 2007 Discontinued for HIV-1 infections in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top